The company Adaptimmune Therapeutics PLC must be used for this project. After reading the course material and research, you will complete the steps below.

Adaptimmune Therapeutics PLC (NMS: ADAP)

Business Summary

Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing cell therapies to patients, particularly in solid tumors. Co. has four SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells in clinical trials: MAGE-A10, an indication for urothelial, melanoma and head and neck cancers; MAGE-A4, an indication for urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal and gastric cancers; Alpha Fetoprotein, a therapeutic candidate in hepatocellular carcinoma; and NY-ESO in Synovial Sarcoma, myxoid round cell liposarcoma and NSCLC; and NY-ESO + Keytruda in multiple myeloma.